(Q79722380)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17279580%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

editorial

0 references

title

Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17279580%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

main subject

acute myeloid leukemia

1 reference

Hagop M Kantarjian

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17279580%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

1 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17279580%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

number of pages

4

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17279580%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17279580%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17279580%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

1007-1010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17279580%20AND%20SRC:MED&resulttype=core&format=json

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

25 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

The outcomes and costs of acute myeloid leukemia among the elderly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22502

7 January 2021

Identifiers

DOI

10.1002/CNCR.22502

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17279580%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference